Guidance

The production of national guidance has been an important role for the Association over many years.

In recent years the ABS has developed its symptomatic guidelines into Surgical Guidelines for the Management of Breast Cancer to ensure that treatment standards are the same regardless of whether patients were diagnosed through the NHS Breast Screening Programme or symptomatically.

In recent years it has also produced a Yearbook to update its members on the work of the Association, its audits and other areas of interest.

The ABS will be providing detailed guidance on the following topics in due course. While this is being developed the following guidance may be of use.

 

 


Breast Screening

 

NHSBSP: Clinical Guidance for Breast Cancer Screening Assessment

QA Guidelines for Surgeons in Breast Cancer Screening


Cancer Diagnosis

 

Best practice diagnostic guidelines for patients presenting with breast symptoms


Treatment Guidelines

 

Early and locally advanced breast cancer: diagnosis and treatment (CG80)

Advanced breast cancer: diagnosis and treatment (CG81)


Neoadjuvant Treatment

 

Pertusamab for the neoadjuvant treatment of HER2- positive breast cancer (TA424)


Cancer Surgery

 

ABS Surgical Guidelines for the management of breast cancer (2009)

ABS Consensus statement on Margins in BCS for Early Breast Cancer & DCIS 

Contralateral Prophylactic Mastectomy Consensus Statement: Additional Considerations and a framework for shared decision making 

Contralateral Prophylactic Mastectomy (CPM) Consensus Statement: Data on CPM outcomes and risks 

Contralateral Mastectomy: ABS Summary Document

Management of the Malignant Axilla in Early Breast Cancer

ABS Summary Statement: Use of Blue Dye for SNLB

Intraoperative tests (RD 100i OSNA system and Metasin test) for detecting sentinel lymph node metastases in breast cancer (DG8)


Oncoplastic/Reconstructive Surgery

 

ALCL: ABS Summary Document

Acellular Dermal Matrix assisted breast reconstruction procedures: Joint Guidelines from the ABS & BAPRAS

Oncoplastic Breast Reconstruction: Guidelines for Best Practice 

Lipomodelling Guidelines for Breast Surgery 

Breast reconstruction using lipomodelling after breast cancer treatment (IPG417)


Adjuvant Treatment

 

Benefits of Adjuvant Bisphosphonates in Post menopausal women

Update on optimal duration of adjuvant antihormonal therapy

Hormonal Therapies for the adjuvant treatment of early oestrogen-receptor-positive breast cancer (TA112)

Gene expression profiling and expanded immunohistochemistry tests for guiding adjuvant chemotherapy decisions in early breast cancer management: MammaPrint, Oncotype DX, IHC4 and Mammostrat (DG10)


Cancer Care

 

ABS Summary Statement: Duration and frequency of surveillance mammography after primary breast cancer treatment

Liposuction for chronic lymphoedema (IPG251)

ABS Consensus Statement on breast operation note documentation

ABS Summary Statement on antibiotic prophylaxis in breast surgery

Pregnancy and Breast Cancer (RCOG 2011)


Family History

 

ABS Summary Statement on Chemoprevention for women with no personal history of breast cancer

Familial breast cancer: classification, care and managing breast cancer and related risks in people with a family history of breast cancer

ABS overview of the implications and implementation of NICE guideliens on Familial Breast Cancer (CG164)


Service Guidance

 

Improving outcomes in breast cancer (CSG1)

NICE Quality Standard: Breast Cancer (QS12)


Guideline Archive

 

The management of metastatic bone disease in the UK

The training of a general surgeon with an interest in breast disease


Please note, where a document is described as an 'ABS Consensus Statement', this refers to an agreement between ABS members after debate at an ABS Conference or ABS MDT Meeting. An 'ABS Summary Document' refers to a document created by ABS Committees.